1 | Study | 1.53% | |
2 | Cancer | 1.32% | |
3 | Health | 1.26% | |
4 | Case | 0.82% | |
5 | Patients | 0.8% | |
6 | Report | 0.73% | |
7 | Disease | 0.66% | |
8 | Risk | 0.66% | |
9 | New | 0.64% | |
10 | BMC | 0.59% | |
11 | HIV | 0.46% | |
12 | Breast | 0.41% | |
13 | May | 0.41% | |
14 | Patient | 0.41% | |
15 | Acute | 0.37% | |
16 | AI | 0.3% | |
17 | Lung | 0.3% | |
18 | Syndrome | 0.3% | |
19 | Africa | 0.28% | |
20 | Treatment | 0.28% | |
21 | Early | 0.28% | |
22 | Vaccine | 0.28% | |
23 | Human | 0.27% | |
24 | Brain | 0.27% | |
25 | Heart | 0.27% | |
26 | Liver | 0.25% | |
27 | Linked | 0.25% | |
28 | Public | 0.23% | |
29 | Prostate | 0.23% | |
30 | Nigeria | 0.21% | |
31 | World | 0.21% | |
32 | Care | 0.21% | |
33 | Parkinsons | 0.21% | |
34 | Clinical | 0.21% | |
35 | Review | 0.21% | |
36 | Not | 0.2% | |
37 | Management | 0.2% | |
38 | First | 0.2% | |
39 | Researchers | 0.2% | |
40 | Medicine | 0.2% | |
41 | Use | 0.18% | |
42 | COVID-19 | 0.18% | |
43 | Diet | 0.18% | |
44 | Trial | 0.18% | |
45 | Exercise | 0.18% | |
46 | Blood | 0.18% | |
47 | Rare | 0.18% | |
48 | COVID | 0.18% | |
49 | Therapy | 0.18% | |
50 | South | 0.16% | |
는 분류, 데이터 기준으로 의 기사에서 의 고유명사 데이터를 통해 생성되었습니다.
|
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
AJMC.com Managed Markets Network
2024-04-19 05:29:24
Trial for immunotherapy drug shows promise for aggressive breast cancer
Medical Xpress
2024-04-19 02:24:04
Study Uncovers Potential Immunotherapy Approach for Rare Eye Cancer
Technology Networks
2024-04-18 18:21:37
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
AJMC.com Managed Markets Network
2024-04-18 07:04:25
Cureus
2024-04-18 05:04:13
Medical.Net
2024-04-18 01:43:00
Prostate cancer salvage therapy guideline incorporates PSMA-PET imaging
Urology Times
2024-04-17 23:03:38
StreetInsider.com
2024-04-16 12:53:00
UroToday
2024-04-16 06:18:48
High-efficacy therapy found to cut disability progression in pediatric MS study
Medical Xpress
2024-04-16 03:10:04
PR Newswire
2024-04-15 16:30:00